These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23726024)

  • 1. Anti-CD3 clinical trials in type 1 diabetes mellitus.
    Daifotis AG; Koenig S; Chatenoud L; Herold KC
    Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Otelixizumab in the treatment of type 1 diabetes mellitus.
    Sprangers B; Van der Schueren B; Gillard P; Mathieu C
    Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teplizumab for treatment of type 1 diabetes mellitus.
    Skelley JW; Elmore LK; Kyle JA
    Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD3 mAbs for treatment of type 1 diabetes.
    Kaufman A; Herold KC
    Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus.
    Wiczling P; Rosenzweig M; Vaickus L; Jusko WJ
    J Clin Pharmacol; 2010 May; 50(5):494-506. PubMed ID: 19934031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
    Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
    Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
    Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
    Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
    Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
    N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
    Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
    Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
    Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
    Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention versus intervention of type 1 diabetes.
    Brooks-Worrell B; Palmer JP
    Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
    Miller SA; St Onge E
    Expert Opin Biol Ther; 2011 Nov; 11(11):1525-32. PubMed ID: 21913874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?
    Herold KC; Taylor L
    Immunol Res; 2003; 28(2):141-50. PubMed ID: 14610290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.
    Alkemade GM; Hilbrands R; Vandemeulebroucke E; Pipeleers D; Waldmann H; Mathieu C; Keymeulen B; Roep BO
    Diabetes Metab Res Rev; 2011 Nov; 27(8):925-7. PubMed ID: 22069286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study.
    Ambery P; Donner TW; Biswas N; Donaldson J; Parkin J; Dayan CM
    Diabet Med; 2014 Apr; 31(4):399-402. PubMed ID: 24236828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
    Ramos EL; Dayan CM; Chatenoud L; Sumnik Z; Simmons KM; Szypowska A; Gitelman SE; Knecht LA; Niemoeller E; Tian W; Herold KC;
    N Engl J Med; 2023 Dec; 389(23):2151-2161. PubMed ID: 37861217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
    Vudattu NK; Herold KC
    Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
    Tooley JE; Vudattu N; Choi J; Cotsapas C; Devine L; Raddassi K; Ehlers MR; McNamara JG; Harris KM; Kanaparthi S; Phippard D; Herold KC
    Eur J Immunol; 2016 Jan; 46(1):230-41. PubMed ID: 26518356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
    Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
    Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
    Vlasakakis G; Napolitano A; Barnard R; Brown K; Bullman J; Inman D; Keymeulen B; Lanham D; Leirens Q; MacDonald A; Mezzalana E; Page K; Patel M; Savage CO; Zamuner S; van Maurik A
    Br J Clin Pharmacol; 2019 Apr; 85(4):704-714. PubMed ID: 30566758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.